Phase I and pharmacological study of the new topoisomerase I inhibitor GI147211, using a daily x 5 intravenous administration.

Topoisomerase I inhibitors are interesting anti-cancer agents with a novel mechanism of action. We performed a phase I study with intravenous GI147211, a new semisynthetic camptothecin analogue, using a daily x 5 schedule administered every 3 weeks, to evaluate the side-effects and pharmacokinetics...

Descripción completa

Detalles Bibliográficos
Autores principales: Gerrits, C. J., Creemers, G. J., Schellens, J. H., Wissel, P., Planting, A. S., Kunka, R., Selinger, K., de Boer-Dennert, M., Marijnen, Y., Harteveld, M., Verweij, J.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1996
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2074382/
https://www.ncbi.nlm.nih.gov/pubmed/8611374

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2074382/
https://www.ncbi.nlm.nih.gov/pubmed/8611374

Ejemplares similares